Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Among authors: barretina ginesta mp. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y, de Juan Ferré A, Mendiola C, Barretina-Ginesta MP, Gaba Garcia L, Santaballa Bertrán A, Bover Barcelo I, Gil-Martin M, Manzano A, Rubio Pérez MJ, Romeo Marin M, Arqueros Núñez C, García-Martínez E, Gonzalez Martin A. Garcia Garcia Y, et al. Int J Gynecol Cancer. 2019 Jul;29(6):1050-1056. doi: 10.1136/ijgc-2019-000256. Int J Gynecol Cancer. 2019. PMID: 31263024 Clinical Trial.
Rare ovarian tumours. Other treatments for ovarian cancer.
Gil-Martin M, Pardo B, Barretina-Ginesta MP. Gil-Martin M, et al. EJC Suppl. 2020 Aug 22;15:96-103. doi: 10.1016/j.ejcsup.2019.11.002. eCollection 2020 Aug. EJC Suppl. 2020. PMID: 33240448 Free PMC article.
SEOM-GEICO clinical guidelines on endometrial cancer (2021).
Barretina-Ginesta MP, Quindós M, Alarcón JD, Esteban C, Gaba L, Gómez C, Fidalgo JAP, Romero I, Santaballa A, Rubio-Pérez MJ. Barretina-Ginesta MP, et al. Clin Transl Oncol. 2022 Apr;24(4):625-634. doi: 10.1007/s12094-022-02799-7. Epub 2022 Mar 21. Clin Transl Oncol. 2022. PMID: 35312947 Free PMC article.
GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee.
Woopen H, Sehouli J, Davis A, Lee YC, Cohen PA, Ferrero A, Gleeson N, Jhingran A, Kajimoto Y, Mayadev J, Barretina-Ginesta MP, Sundar S, Suzuki N, van Dorst E, Joly F. Woopen H, et al. Cancer Treat Rev. 2022 Jun;107:102396. doi: 10.1016/j.ctrv.2022.102396. Epub 2022 May 2. Cancer Treat Rev. 2022. PMID: 35525106 Free article. Review.
Erratum to "GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee" [Cancer Treatm. Rev. 107 (2022) 102396].
Woopen H, Sehouli J, Davis A, Lee YC, Cohen PA, Ferrero A, Gleeson N, Jhingran A, Kajimoto Y, Mayadev J, Barretina-Ginesta MP, Sundar S, Suzuki N, van Dorst E, Joly F. Woopen H, et al. Cancer Treat Rev. 2022 Sep;109:102431. doi: 10.1016/j.ctrv.2022.102431. Epub 2022 Jul 5. Cancer Treat Rev. 2022. PMID: 35803179 No abstract available.
Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.
Plaja A, Teruel I, Ochoa-de-Olza M, Cucurull M, Arroyo ÁJ, Pardo B, Ortiz I, Gil-Martin M, Piulats JM, Pla H, Fina C, Carbó A, Barretina-Ginesta MP, Martínez-Román S, Carballas E, González A, Esteve A, Romeo M. Plaja A, et al. Among authors: barretina ginesta mp. Int J Mol Sci. 2023 Jul 13;24(14):11420. doi: 10.3390/ijms241411420. Int J Mol Sci. 2023. PMID: 37511180 Free PMC article.
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).
Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, García García Y, Romeo M, Iglesias M, de Juan Ferré A, Barretina-Ginesta MP, Manzano A, Gaba L, Rubio MJ, de Andrea CE, González-Martín A. Tavira B, et al. Among authors: barretina ginesta mp. Clin Cancer Res. 2024 Jan 5;30(1):176-186. doi: 10.1158/1078-0432.CCR-23-0771. Clin Cancer Res. 2024. PMID: 37527007 Free PMC article.
29 results